North America Musculoskeletal Diseases Market

North American Musculoskeletal Diseases Market Size

The size of the North America musculoskeletal diseases market was worth USD 1.81 billion in 2024. The market is projected to reach USD 2.94 billion by 2033 from USD 1.91 billion in 2025, at a CAGR of 5.54% from 2025 to 2033

MARKET DRIVERS

Rising Incidence and Awareness Drive Musculoskeletal Diseases

Due to the Y-O-Y growth in the frequency of musculoskeletal illnesses, the North American musculoskeletal diseases treatment market has grown significantly over the years.

Increased employment pressure, poor fitness and health habits, and incorrect postures are all symptoms of musculoskeletal illnesses. In addition, ligaments, tendons, cartilage, and spinal discs are musculoskeletal ailments and diseases that are quickly growing, according to recent data. The market is likely to develop as a result of this. The key drivers driving market expansion are increased public awareness of musculoskeletal illnesses, the development of efficient and sophisticated technologies in developed nations, and the commercialization of pipeline medications.

Furthermore, market growth is likely to be influenced by supporting government activities across the region, growing healthcare spending, and embracing musculoskeletal illness medications. Furthermore, the large number of unmet medical requirements in emerging nations is expected to boost the market growth. The adoption of musculoskeletal illness pharmaceuticals opens up the attractive potential for market participants in growing countries, projected to drive the musculoskeletal disease market forward.

The market is likely to increase in the coming years as new entrants and current market players adopt creative measures and technology improvements to enhance the quality and efficacy of musculoskeletal illness treatment scans. This is expected to propel the market further.

MARKET RESTRAINTS

High Costs and Regulatory Barriers Restrain Musculoskeletal Treatment

The high cost of musculoskeletal illness medication research and development, which is out of reach for developing nations, has been a limiting factor of the market. Strict government regulations and a lengthy government approval procedure are also projected to hamper the market's expansion. The biggest issue for hospitals is the danger of musculoskeletal illness treatment side effects. It is impeding market expansion. Heavy-duty medication usage in the treatment of musculoskeletal pain is both insufficient and inconsistent; solid research is needed to support therapeutic practice. Factors like this are expected to restrain the growth of the North American Musculoskeletal Diseases Market.

REPORT COVERAGE

REGIONAL ANALYSIS

North America has a significant market share due to the increase in the biological drug used for treating various musculoskeletal conditions, increased access to medical and healthcare facilities, and the introduction of novel biologics.

Musculoskeletal disease market growth is driven by the availability of medical and healthcare facilities in this region and increases in healthcare spending. About 31 million Americans suffer from osteoarthritis, the most common type of arthritis. There are expected to be over 78 million people with arthritis by 2040. In 2018, there were 1.3 million people with RA in the United States. The risk of RA is about two to three times higher among women than men. RA has a lifetime risk of 3.6 percent for women and 1.7 percent for men. RA can attack at any age, even infants. As a result, this region is expected to have a lot of potential growth.

North America's Musculoskeletal Diseases Market is predicted to be dominated by the United States. To obtain a competitive edge, these businesses concentrate their efforts on producing low-cost, easy-to-use medications that successfully promote bone formation. However, due to a lack of appropriate treatments and medications, this market is expected to rise at a rapid pace.

Canada is expected to have a significant market share during the forecast period. Another factor boosting the need for musculoskeletal drugs in Canada is the rising frequency of bone abnormalities and joint-related injuries.

KEY MARKET PLAYERS

AbGenomics International, AB Sciences, Ablynx, Akron Molecules, Johnson & Johnson, F. Hoffmann-La Roche, Pfizer, Eli Lilly, Adheron, Alder BioPharmaceuticals, Bioiberica, Bone Therapeutics, Edding Pharm, Boehringer Ingelheim, Can-Fite BioPharma, Celltrion, Celgene Corp., Cellular Biomedicine, ChemoCentryx, Cerapedics, , Eupraxia Pharmaceuticals, and GlaxoSmithKline are the some of the key players in the North America Musculoskeletal Diseases market.

MARKET SEGMENTATION

This research report on the North American musculoskeletal diseases market has been segmented and sub-segmented into the following categories.

By Type

• Rheumatoid Arthritis
• Osteoarthritis
• Osteoporosis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Fibromyalgia
• Others

By Type of Molecules

• Biologics
• Small Molecules

By Treatment

• Biologics
• Corticosteroids
• Parathyroid Hormone
• Protein Therapy
• Selective Estrogen Receptor Modulators
• Synthetic Bone Graft
• Composite Grafts
• Demineralized Bone Matrix
• BMPS

By Country

• The United States
• Canada
• Rest of North America